BERLIN--(BUSINESS WIRE)--MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy. The results of this phase II clinical trial will serve as the basis for the conformity evaluation procedure required under the German Medical Devices Act (Medizinproduktegesetz).
